

Iraq

Population 2017

38 million

Estimates of TB burden*, 2017	Number (thousands)	Rate (per 100 000 population)
Mortality (excludes HIV+TB)	1.1 (0.83–1.4)	2.9 (2.2–3.7)
Mortality (HIV+TB only)	<0.01 (<0.01–<0.01)	0.02 (0.01–0.02)
Incidence (includes HIV+TB)	16 (14–18)	42 (37–48)
Incidence (HIV+TB only)	0.016 (0.013–0.02)	0.04 (0.03–0.05)
Incidence (MDR/RR-TB)**	1.3 (0.93–1.8)	3.5 (2.4–4.8)

Estimated TB incidence by age and sex (thousands)*, 2017			
	0-14 years	> 14 years	Total
Females	0.86 (0.84–0.89)	7.5 (6.8–8.1)	8.3 (7.6–9.1)
Males	0.95 (0.93–0.98)	6.8 (6.3–7.4)	7.8 (7.1–8.4)
Total	1.8 (1.7–1.9)	14 (13–16)	16 (14–18)

TB case notifications, 2017	
Total cases notified	7 853
Total new and relapse	7 644
- % tested with rapid diagnostics at time of diagnosis	
- % with known HIV status	54%
- % pulmonary	57%
- % bacteriologically confirmed among pulmonary	62%

Universal health coverage and social protection	
TB treatment coverage (notified/estimated incidence), 2017	47% (42–54)
TB patients facing catastrophic total costs	
TB case fatality ratio (estimated mortality/estimated incidence), 2017	0.07 (0.05–0.09)

TB/HIV care in new and relapse TB patients, 2017		
	Number	(%)
Patients with known HIV-status who are HIV-positive	0	0%
- on antiretroviral therapy	0	

Drug-resistant TB care, 2017			
	New cases	Previously treated cases	Total number***
Estimated MDR/RR-TB cases among notified pulmonary TB cases			420 (350–500)
Estimated % of TB cases with MDR/RR-TB	6.1% (4.5–8)	30% (25–35)	
% notified tested for rifampicin resistance	78%	73%	6 101
MDR/RR-TB cases tested for resistance to second-line drugs			100
Laboratory-confirmed cases		MDR/RR-TB: 100, XDR-TB: 5	
Patients started on treatment ****		MDR/RR-TB: 100, XDR-TB: 0	

Treatment success rate and cohort size		
	Success	Cohort
New and relapse cases registered in 2016	93%	7 246
Previously treated cases, excluding relapse, registered in 2016	93%	71
HIV-positive TB cases registered in 2016		0
MDR/RR-TB cases started on second-line treatment in 2015	56%	73
XDR-TB cases started on second-line treatment in 2015		

TB preventive treatment, 2017	
% of HIV-positive people (newly enrolled in care) on preventive treatment	
% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment	> 100%

TB financing, 2018	
National TB budget (US\$ millions)	24
Funding source: 84% domestic, 6% international, 9% unfunded	

* Ranges represent uncertainty intervals


** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin

*** Includes cases with unknown previous TB treatment history

**** Includes patients diagnosed before 2017 and patients who were not laboratory-confirmed


Tuberculosis profile

(Rate per 100 000 population per year)




— Mortality (excludes HIV+TB)

(Rate per 100 000 population per year)




— Incidence
— Notified (new and relapse)
— Incidence (HIV+TB only)

Notified cases by age group and sex, 2017




Treatment success rate (%)



— New and relapse
— Retreatment, excluding relapse
— HIV-positive — MDR/RR-TB — XDR-TB

Total budget (US\$ millions)



— Unfunded
— Funded internationally
— Funded domestically